Improving Access to Care: CADTH’s Perspective
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Improving Access to Care: CADTH’s Perspective

on

  • 391 views

Improving Access to Care: CADTH’s Perspective

Improving Access to Care: CADTH’s Perspective
Presented by Dr. Brian O’Rourke, CADTH President and CEO
on April 18, 2013

Statistics

Views

Total Views
391
Views on SlideShare
391
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Improving Access to Care: CADTH’s Perspective Presentation Transcript

  • 1. Improving Access to Care: CADTH’s Perspective Dr. Brian O’Rourke CADTH President and CEO April 18, 2013
  • 2. Canadian Agency for Drugs and Technologies in Health (CADTH)  Founded in 1989  Private, not-for-profit corporation  Funded by Health Canada, the provinces and territories  140 employees, $21.5M budget CADTH supports informed decisions by providing impartial, evidence-based research and advice on drugs and other health technologies.
  • 3. Patient and Public Engagement in the Common Drug Review Public Citizens interested in health care system efficiency and fairness Patient Someone with a health condition who receives a service 2010 Patient input process • Provides patient perspectives • Incorporated systematically 2006 2 public members on the Canadian Drug Expert Committee (CDEC) • Provide public perspective • Have full voting rights
  • 4. Patient Input Submission Includes: • Information about submitting group • Impact of condition and current treatment on patients o Issues and outcomes of importance o Benefits and adverse effects o Unmet needs • Experience with or expectations for new drug • Additional information
  • 5. How Patient Input Is Used Patient input collated, summarized, used to inform protocol and included review report Patient input presented, used in deliberations and reflected in recommendations CADTH Review Team Expert Committee Drug Plans Patient input shared Patient Input Submission Canadian Patient Groups Reasons and recommendations published Original input and summary sent to CDEC Patient input shared Patient evidence shared Patient evidence shared Patient input shared Patient input shared
  • 6. • Patient input process is on par with, or more developed than, the process at most HTA agencies • Process, template, and guidance documents are clear, relevant, and well understood • Learnings from international peers were identified that could be implemented • Need to align all stakeholders on the purpose, value, and credibility of soliciting patient input as evidence in the CDR process 2011-2012 Patient Input Evaluation
  • 7. Next Steps • SECOR Evaluation Report and management response are posted (www.cadth.ca) • Will continue to improve the process: o Phased approach, starting with those that are easy and quick o Using learnings from other organizations • National (e.g., pCODR), international (e.g., NICE, SMC) o Using and/or adapting material already available • Communicate changes • Continue to evaluate and improve
  • 8. CADTH website: www.cadth.ca Twitter: @cadth_acmts For More Information